Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVDX3 in degenerative lumbar spondylolisthesis
NCT05961956Phase 2Active, not recruiting
- Sponsor
- Novadip Biosciences
- Start
- Oct 2023
- Primary completion
- Apr 2026
- Modality
- Implantable Devices, Implantable Hydrogels, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NVD-X3 in degenerative lumbar spondylolisthesis (DLS), sponsored by Novadip Biosciences. Primary endpoint: Primary Safety Endpoint at 24 months. Started Oct 2023; status: active, not recruiting.
02
Drugs
NVD-X3
03
Conditions
degenerative lumbar spondylolisthesis (DLS)
Beyond the preview
Go deeper on NCT05961956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05961956.